Reuters logo
Dialysis chain DaVita wins approval to buy Renal Ventures with conditions
March 28, 2017 / 5:17 PM / 8 months ago

Dialysis chain DaVita wins approval to buy Renal Ventures with conditions

WASHINGTON (Reuters) - Kidney dialysis company DaVita, Inc (DVA.N) has won antitrust approval to buy rival Renal Ventures Management LLC on condition that it sell five clinics, the Federal Trade Commission said on Tuesday.

The clinics to be divested are in New Jersey and Texas, the agency said.

Reporting by Diane Bartz; Editing by Chizu Nomiyama

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below